Cargando…
Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT
Kanack and colleagues analyze anti-platelet factor 4 antibodies from 5 patients with vaccine-induced thrombotic thrombocytopenia (VITT) secondary to COVID-19 adenoviral vaccination and antibodies from patients with spontaneous heparin-induced thrombocytopenia (HIT) and classical HIT. VITT antibodies...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262283/ https://www.ncbi.nlm.nih.gov/pubmed/35560046 http://dx.doi.org/10.1182/blood.2021014588 |
_version_ | 1784742460206874624 |
---|---|
author | Kanack, Adam J. Bayas, Antonios George, Gemlyn Abou-Ismail, Mouhamed Yazan Singh, Bandana Kohlhagen, Mindy C. Splinter, Noah P. Christ, Monika Naumann, Markus Moser, Karen A. Smock, Kristi J. Grazioli, Alison Wen, Renren Wang, Demin Murray, David L. Padmanabhan, Anand |
author_facet | Kanack, Adam J. Bayas, Antonios George, Gemlyn Abou-Ismail, Mouhamed Yazan Singh, Bandana Kohlhagen, Mindy C. Splinter, Noah P. Christ, Monika Naumann, Markus Moser, Karen A. Smock, Kristi J. Grazioli, Alison Wen, Renren Wang, Demin Murray, David L. Padmanabhan, Anand |
author_sort | Kanack, Adam J. |
collection | PubMed |
description | Kanack and colleagues analyze anti-platelet factor 4 antibodies from 5 patients with vaccine-induced thrombotic thrombocytopenia (VITT) secondary to COVID-19 adenoviral vaccination and antibodies from patients with spontaneous heparin-induced thrombocytopenia (HIT) and classical HIT. VITT antibodies are monoclonal or oligoclonal, similar to spontaneous HIT, whereas classical HIT antibodies are polyclonal. Heparin inhibits antibody-induced platelet activation in VITT, suggesting that heparin should be considered for the treatment of VITT. |
format | Online Article Text |
id | pubmed-9262283 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-92622832022-07-08 Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT Kanack, Adam J. Bayas, Antonios George, Gemlyn Abou-Ismail, Mouhamed Yazan Singh, Bandana Kohlhagen, Mindy C. Splinter, Noah P. Christ, Monika Naumann, Markus Moser, Karen A. Smock, Kristi J. Grazioli, Alison Wen, Renren Wang, Demin Murray, David L. Padmanabhan, Anand Blood Letter to Blood Kanack and colleagues analyze anti-platelet factor 4 antibodies from 5 patients with vaccine-induced thrombotic thrombocytopenia (VITT) secondary to COVID-19 adenoviral vaccination and antibodies from patients with spontaneous heparin-induced thrombocytopenia (HIT) and classical HIT. VITT antibodies are monoclonal or oligoclonal, similar to spontaneous HIT, whereas classical HIT antibodies are polyclonal. Heparin inhibits antibody-induced platelet activation in VITT, suggesting that heparin should be considered for the treatment of VITT. American Society of Hematology 2022-07-07 /pmc/articles/PMC9262283/ /pubmed/35560046 http://dx.doi.org/10.1182/blood.2021014588 Text en © 2022 by The American Society of Hematology |
spellingShingle | Letter to Blood Kanack, Adam J. Bayas, Antonios George, Gemlyn Abou-Ismail, Mouhamed Yazan Singh, Bandana Kohlhagen, Mindy C. Splinter, Noah P. Christ, Monika Naumann, Markus Moser, Karen A. Smock, Kristi J. Grazioli, Alison Wen, Renren Wang, Demin Murray, David L. Padmanabhan, Anand Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT |
title | Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT |
title_full | Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT |
title_fullStr | Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT |
title_full_unstemmed | Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT |
title_short | Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT |
title_sort | monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate vitt |
topic | Letter to Blood |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262283/ https://www.ncbi.nlm.nih.gov/pubmed/35560046 http://dx.doi.org/10.1182/blood.2021014588 |
work_keys_str_mv | AT kanackadamj monoclonalandoligoclonalantiplateletfactor4antibodiesmediatevitt AT bayasantonios monoclonalandoligoclonalantiplateletfactor4antibodiesmediatevitt AT georgegemlyn monoclonalandoligoclonalantiplateletfactor4antibodiesmediatevitt AT abouismailmouhamedyazan monoclonalandoligoclonalantiplateletfactor4antibodiesmediatevitt AT singhbandana monoclonalandoligoclonalantiplateletfactor4antibodiesmediatevitt AT kohlhagenmindyc monoclonalandoligoclonalantiplateletfactor4antibodiesmediatevitt AT splinternoahp monoclonalandoligoclonalantiplateletfactor4antibodiesmediatevitt AT christmonika monoclonalandoligoclonalantiplateletfactor4antibodiesmediatevitt AT naumannmarkus monoclonalandoligoclonalantiplateletfactor4antibodiesmediatevitt AT moserkarena monoclonalandoligoclonalantiplateletfactor4antibodiesmediatevitt AT smockkristij monoclonalandoligoclonalantiplateletfactor4antibodiesmediatevitt AT graziolialison monoclonalandoligoclonalantiplateletfactor4antibodiesmediatevitt AT wenrenren monoclonalandoligoclonalantiplateletfactor4antibodiesmediatevitt AT wangdemin monoclonalandoligoclonalantiplateletfactor4antibodiesmediatevitt AT murraydavidl monoclonalandoligoclonalantiplateletfactor4antibodiesmediatevitt AT padmanabhananand monoclonalandoligoclonalantiplateletfactor4antibodiesmediatevitt |